Lei Li1, Jinhua Leng1, Shuangzheng Jia1, Jinghe Lang1
1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China
Tóm tắt
AbstractObjectiveTo determine the long‐term effects of using the levonorgestrel‐releasing intrauterine system (LNG‐IUS) to treat symptomatic adenomyosis.MethodA prospective longitudinal study was conducted among 1100 women who received the LNG‐IUS at a tertiary teaching hospital in China between December 10, 2006, and December 24, 2014. All participants had symptomatic adenomyosis (visual analogue scale [VAS] ≥7 and/or pictorial blood loss assessment chart [PBAC] score >100) diagnosed by transvaginal sonography. Follow‐up was at 3, 6, 12, 24, 36, 48, and 60 months after LNG‐IUS placement. The primary outcome was symptom relief. Secondary outcomes included LNG‐IUS retention status; changes in uterine volume; serum levels of cancer antigen 125 (CA125); menstruation pattern; and adverse events.ResultsIn all, 374 (33.7%) participants completed 60 months of LNG‐IUS treatment. The VAS, verbal rating scale, PBAC score, hemoglobin level, uterine volume, and serum CA125 level all showed marked improvements at this time point when compared with baseline (P<0.05 for all comparisons). The cumulative retention rate of LNG‐IUS was 56.2%. Changes in menstruation pattern at 60 months included amenorrhea (n=97, 25.9%) and shortened periods (n=82, 21.9%). The incidence of adverse events was <10% and not considered notable.ConclusionsLong‐term use of LNG‐IUS was effective and acceptable for the treatment of symptomatic adenomyosis.Registered at clinicaltrials.gov (NCT03027648).
